nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—ABCB1—peripheral nervous system neoplasm	0.445	1	CbGaD
Naltrexone—UGT1A1—Etoposide—peripheral nervous system neoplasm	0.102	0.321	CbGbCtD
Naltrexone—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0518	0.163	CbGbCtD
Naltrexone—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0518	0.163	CbGbCtD
Naltrexone—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0359	0.113	CbGbCtD
Naltrexone—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0221	0.0694	CbGbCtD
Naltrexone—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0206	0.0648	CbGbCtD
Naltrexone—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0203	0.0636	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0138	0.0434	CbGbCtD
Naltrexone—Buprenorphine—ABCB1—peripheral nervous system neoplasm	0.000224	0.353	CrCbGaD
Naltrexone—Naloxone—ABCB1—peripheral nervous system neoplasm	0.000222	0.351	CrCbGaD
Naltrexone—Morphine—ABCB1—peripheral nervous system neoplasm	0.000187	0.296	CrCbGaD
Naltrexone—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000131	0.000555	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000553	CcSEcCtD
Naltrexone—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000131	0.000552	CcSEcCtD
Naltrexone—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000131	0.000552	CcSEcCtD
Naltrexone—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.00013	0.00055	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000129	0.000547	CcSEcCtD
Naltrexone—Infection—Etoposide—peripheral nervous system neoplasm	0.000129	0.000547	CcSEcCtD
Naltrexone—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000129	0.000545	CcSEcCtD
Naltrexone—Nausea—Melphalan—peripheral nervous system neoplasm	0.000129	0.000545	CcSEcCtD
Naltrexone—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000542	CcSEcCtD
Naltrexone—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.00054	CcSEcCtD
Naltrexone—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000127	0.000539	CcSEcCtD
Naltrexone—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000127	0.000537	CcSEcCtD
Naltrexone—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000127	0.000537	CcSEcCtD
Naltrexone—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000127	0.000537	CcSEcCtD
Naltrexone—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000127	0.000535	CcSEcCtD
Naltrexone—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000126	0.000534	CcSEcCtD
Naltrexone—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000126	0.000532	CcSEcCtD
Naltrexone—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.00053	CcSEcCtD
Naltrexone—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000528	CcSEcCtD
Naltrexone—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000124	0.000524	CcSEcCtD
Naltrexone—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000523	CcSEcCtD
Naltrexone—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000123	0.000522	CcSEcCtD
Naltrexone—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000522	CcSEcCtD
Naltrexone—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000123	0.00052	CcSEcCtD
Naltrexone—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000123	0.000519	CcSEcCtD
Naltrexone—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000519	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000123	0.000518	CcSEcCtD
Naltrexone—Pain—Cisplatin—peripheral nervous system neoplasm	0.000121	0.000514	CcSEcCtD
Naltrexone—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000512	CcSEcCtD
Naltrexone—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00012	0.000506	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000119	0.000504	CcSEcCtD
Naltrexone—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000502	CcSEcCtD
Naltrexone—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000118	0.0005	CcSEcCtD
Naltrexone—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000118	0.000499	CcSEcCtD
Naltrexone—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000117	0.000495	CcSEcCtD
Naltrexone—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000117	0.000494	CcSEcCtD
Naltrexone—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000494	CcSEcCtD
Naltrexone—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000491	CcSEcCtD
Naltrexone—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000116	0.00049	CcSEcCtD
Naltrexone—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000116	0.000489	CcSEcCtD
Naltrexone—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000489	CcSEcCtD
Naltrexone—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000115	0.000487	CcSEcCtD
Naltrexone—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000486	CcSEcCtD
Naltrexone—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000484	CcSEcCtD
Naltrexone—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000484	CcSEcCtD
Naltrexone—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000114	0.000483	CcSEcCtD
Naltrexone—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000483	CcSEcCtD
Naltrexone—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000114	0.000482	CcSEcCtD
Naltrexone—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000113	0.000479	CcSEcCtD
Naltrexone—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000113	0.000478	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000112	0.000475	CcSEcCtD
Naltrexone—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000112	0.000475	CcSEcCtD
Naltrexone—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000112	0.000474	CcSEcCtD
Naltrexone—Constipation—Etoposide—peripheral nervous system neoplasm	0.000111	0.00047	CcSEcCtD
Naltrexone—Pain—Etoposide—peripheral nervous system neoplasm	0.000111	0.00047	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000111	0.00047	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000111	0.00047	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000466	CcSEcCtD
Naltrexone—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00011	0.000466	CcSEcCtD
Naltrexone—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00011	0.000465	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000457	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000457	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000456	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000454	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000454	CcSEcCtD
Naltrexone—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000107	0.000453	CcSEcCtD
Naltrexone—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000107	0.000452	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.00045	CcSEcCtD
Naltrexone—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000106	0.00045	CcSEcCtD
Naltrexone—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000106	0.000449	CcSEcCtD
Naltrexone—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.000448	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000447	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000447	CcSEcCtD
Naltrexone—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000105	0.000444	CcSEcCtD
Naltrexone—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000105	0.000444	CcSEcCtD
Naltrexone—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000105	0.000442	CcSEcCtD
Naltrexone—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000104	0.000442	CcSEcCtD
Naltrexone—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000103	0.000437	CcSEcCtD
Naltrexone—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000103	0.000435	CcSEcCtD
Naltrexone—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000103	0.000435	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000435	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000435	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000434	CcSEcCtD
Naltrexone—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000102	0.000432	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000102	0.000431	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000431	CcSEcCtD
Naltrexone—Rash—Vincristine—peripheral nervous system neoplasm	0.000101	0.000428	CcSEcCtD
Naltrexone—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000101	0.000428	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000427	CcSEcCtD
Naltrexone—Headache—Vincristine—peripheral nervous system neoplasm	0.000101	0.000425	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000423	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.000422	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	9.92e-05	0.00042	CcSEcCtD
Naltrexone—Nausea—Alitretinoin—peripheral nervous system neoplasm	9.9e-05	0.000419	CcSEcCtD
Naltrexone—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	9.71e-05	0.000411	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—peripheral nervous system neoplasm	9.59e-05	0.000406	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	9.58e-05	0.000405	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—peripheral nervous system neoplasm	9.57e-05	0.000405	CcSEcCtD
Naltrexone—Nausea—Vincristine—peripheral nervous system neoplasm	9.54e-05	0.000403	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	9.52e-05	0.000403	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	9.5e-05	0.000402	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	9.42e-05	0.000399	CcSEcCtD
Naltrexone—Asthenia—Etoposide—peripheral nervous system neoplasm	9.33e-05	0.000395	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	9.33e-05	0.000395	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—peripheral nervous system neoplasm	9.31e-05	0.000394	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	9.27e-05	0.000392	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	9.25e-05	0.000391	CcSEcCtD
Naltrexone—Chills—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000389	CcSEcCtD
Naltrexone—Pruritus—Etoposide—peripheral nervous system neoplasm	9.2e-05	0.000389	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—peripheral nervous system neoplasm	9.07e-05	0.000384	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—peripheral nervous system neoplasm	9.03e-05	0.000382	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—peripheral nervous system neoplasm	8.99e-05	0.00038	CcSEcCtD
Naltrexone—Rash—Cisplatin—peripheral nervous system neoplasm	8.95e-05	0.000379	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—peripheral nervous system neoplasm	8.94e-05	0.000378	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—peripheral nervous system neoplasm	8.93e-05	0.000378	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—peripheral nervous system neoplasm	8.9e-05	0.000376	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	8.87e-05	0.000375	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	8.85e-05	0.000374	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	8.81e-05	0.000373	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—peripheral nervous system neoplasm	8.8e-05	0.000372	CcSEcCtD
Naltrexone—Tension—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.000371	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	8.75e-05	0.00037	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—peripheral nervous system neoplasm	8.68e-05	0.000367	CcSEcCtD
Naltrexone—Back pain—Epirubicin—peripheral nervous system neoplasm	8.64e-05	0.000366	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	8.61e-05	0.000364	CcSEcCtD
Naltrexone—Dizziness—Etoposide—peripheral nervous system neoplasm	8.6e-05	0.000364	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	8.59e-05	0.000363	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	8.58e-05	0.000363	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.56e-05	0.000362	CcSEcCtD
Naltrexone—Chills—Doxorubicin—peripheral nervous system neoplasm	8.52e-05	0.00036	CcSEcCtD
Naltrexone—Nausea—Cisplatin—peripheral nervous system neoplasm	8.43e-05	0.000357	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—peripheral nervous system neoplasm	8.42e-05	0.000356	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—peripheral nervous system neoplasm	8.39e-05	0.000355	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	8.32e-05	0.000352	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	8.29e-05	0.000351	CcSEcCtD
Naltrexone—Vomiting—Etoposide—peripheral nervous system neoplasm	8.27e-05	0.00035	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	8.27e-05	0.00035	CcSEcCtD
Naltrexone—Agitation—Epirubicin—peripheral nervous system neoplasm	8.21e-05	0.000347	CcSEcCtD
Naltrexone—Rash—Etoposide—peripheral nervous system neoplasm	8.2e-05	0.000347	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—peripheral nervous system neoplasm	8.19e-05	0.000347	CcSEcCtD
Naltrexone—Headache—Etoposide—peripheral nervous system neoplasm	8.15e-05	0.000345	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—peripheral nervous system neoplasm	8.15e-05	0.000345	CcSEcCtD
Naltrexone—Tension—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	0.000343	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	8.09e-05	0.000342	CcSEcCtD
Naltrexone—Malaise—Epirubicin—peripheral nervous system neoplasm	8.06e-05	0.000341	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—peripheral nervous system neoplasm	8.03e-05	0.00034	CcSEcCtD
Naltrexone—Syncope—Epirubicin—peripheral nervous system neoplasm	8.01e-05	0.000339	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—peripheral nervous system neoplasm	8e-05	0.000338	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	7.95e-05	0.000336	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—peripheral nervous system neoplasm	7.89e-05	0.000334	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	7.85e-05	0.000332	CcSEcCtD
Naltrexone—Cough—Epirubicin—peripheral nervous system neoplasm	7.8e-05	0.00033	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	7.79e-05	0.00033	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—peripheral nervous system neoplasm	7.74e-05	0.000327	CcSEcCtD
Naltrexone—Nausea—Etoposide—peripheral nervous system neoplasm	7.73e-05	0.000327	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000326	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	7.67e-05	0.000324	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.000322	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.000322	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—peripheral nervous system neoplasm	7.61e-05	0.000322	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—peripheral nervous system neoplasm	7.6e-05	0.000321	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—peripheral nervous system neoplasm	7.58e-05	0.000321	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	7.55e-05	0.000319	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—peripheral nervous system neoplasm	7.51e-05	0.000318	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—peripheral nervous system neoplasm	7.45e-05	0.000315	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—peripheral nervous system neoplasm	7.44e-05	0.000315	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—peripheral nervous system neoplasm	7.41e-05	0.000314	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000311	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—peripheral nervous system neoplasm	7.3e-05	0.000309	CcSEcCtD
Naltrexone—Oedema—Epirubicin—peripheral nervous system neoplasm	7.29e-05	0.000308	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	7.29e-05	0.000308	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	7.27e-05	0.000307	CcSEcCtD
Naltrexone—Infection—Epirubicin—peripheral nervous system neoplasm	7.24e-05	0.000306	CcSEcCtD
Naltrexone—Cough—Doxorubicin—peripheral nervous system neoplasm	7.21e-05	0.000305	CcSEcCtD
Naltrexone—Shock—Epirubicin—peripheral nervous system neoplasm	7.17e-05	0.000303	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—peripheral nervous system neoplasm	7.16e-05	0.000303	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	7.15e-05	0.000302	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000302	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—peripheral nervous system neoplasm	7.12e-05	0.000301	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.08e-05	0.0003	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	7.05e-05	0.000298	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000298	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000298	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—peripheral nervous system neoplasm	7.04e-05	0.000298	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000297	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000296	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—peripheral nervous system neoplasm	6.95e-05	0.000294	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—peripheral nervous system neoplasm	6.95e-05	0.000294	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	6.88e-05	0.000291	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000288	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—peripheral nervous system neoplasm	6.75e-05	0.000285	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	6.75e-05	0.000285	CcSEcCtD
Naltrexone—Infection—Doxorubicin—peripheral nervous system neoplasm	6.7e-05	0.000283	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	6.64e-05	0.000281	CcSEcCtD
Naltrexone—Shock—Doxorubicin—peripheral nervous system neoplasm	6.64e-05	0.000281	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	6.62e-05	0.00028	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.000279	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000278	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	6.55e-05	0.000277	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	6.55e-05	0.000277	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.000276	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	6.5e-05	0.000275	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000274	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—peripheral nervous system neoplasm	6.43e-05	0.000272	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000268	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000266	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000266	CcSEcCtD
Naltrexone—Constipation—Epirubicin—peripheral nervous system neoplasm	6.23e-05	0.000264	CcSEcCtD
Naltrexone—Pain—Epirubicin—peripheral nervous system neoplasm	6.23e-05	0.000264	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.15e-05	0.00026	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000258	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	6.06e-05	0.000256	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	6.01e-05	0.000254	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	6.01e-05	0.000254	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.000254	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.000252	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000248	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000246	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000246	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000245	CcSEcCtD
Naltrexone—Pain—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000244	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000244	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000244	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.76e-05	0.000244	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	5.56e-05	0.000235	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.000233	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	5.37e-05	0.000227	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—peripheral nervous system neoplasm	5.36e-05	0.000227	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000226	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	5.33e-05	0.000226	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.23e-05	0.000221	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—peripheral nervous system neoplasm	5.16e-05	0.000218	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.99e-05	0.000211	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.00021	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.84e-05	0.000205	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000204	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.77e-05	0.000202	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000196	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.62e-05	0.000195	CcSEcCtD
Naltrexone—Rash—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000194	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.59e-05	0.000194	CcSEcCtD
Naltrexone—Headache—Epirubicin—peripheral nervous system neoplasm	4.57e-05	0.000193	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000189	CcSEcCtD
Naltrexone—Nausea—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000183	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000181	CcSEcCtD
Naltrexone—Rash—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.00018	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.00018	CcSEcCtD
Naltrexone—Headache—Doxorubicin—peripheral nervous system neoplasm	4.23e-05	0.000179	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000169	CcSEcCtD
